Literature DB >> 9364005

Identification of tamoxifen-DNA adducts formed by 4-hydroxytamoxifen quinone methide.

M M Marques1, F A Beland.   

Abstract

Tamoxifen is a liver carcinogen in rats and has been shown to increase the risk of endometrial cancer in women. Recent reports of DNA adducts in leucocyte and endometrial samples from women treated with tamoxifen indicate that it may be genotoxic to humans. One of the proposed pathways for the metabolic activation of tamoxifen involves oxidation to 4-hydroxytamoxifen, which may be further oxidized to an electrophilic quinone methide. In the present study we show that 4-hydroxytamoxifen quinone methide reacts with DNA to form covalent adducts. The major products, which result from 1,8-addition of the exocyclic nitrogen of deoxyguanosine to the conjugated system of 4-hydroxytamoxifen quinone methide, are characterized as (E)- and (Z)-alpha-(deoxyguanosin-N2-yl)-4-hydroxytamoxifen.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9364005     DOI: 10.1093/carcin/18.10.1949

Source DB:  PubMed          Journal:  Carcinogenesis        ISSN: 0143-3334            Impact factor:   4.944


  11 in total

1.  Effect of Nucleosome Assembly on Alkylation by a Dynamic Electrophile.

Authors:  Shane R Byrne; Kun Yang; Steven E Rokita
Journal:  Chem Res Toxicol       Date:  2019-03-27       Impact factor: 3.739

2.  Quinone Methide Bioactivation Pathway: Contribution to Toxicity and/or Cytoprotection?

Authors:  Judy L Bolton
Journal:  Curr Org Chem       Date:  2014-01-01       Impact factor: 2.180

3.  Antiestrogens and the formation of DNA damage in rats: a comparison.

Authors:  Sung Yeon Kim; Naomi Suzuki; Y R Santosh Laxmi; Atsushi Umemoto; Tomonari Matsuda; Shinya Shibutani
Journal:  Chem Res Toxicol       Date:  2006-06       Impact factor: 3.739

4.  CYP3A4-Mediated oxygenation versus dehydrogenation of raloxifene.

Authors:  Chad D Moore; Christopher A Reilly; Garold S Yost
Journal:  Biochemistry       Date:  2010-06-01       Impact factor: 3.162

5.  Photochemical transformation and phototoxicity of 1-aminopyrene.

Authors:  Kui Zeng; Huey-Min Hwang; Shiming Dong; Xiaochun Shi; Kaneytta Wilson; Jacinta Green; Yuguo Jiao; Hongtao Yu
Journal:  Environ Toxicol Chem       Date:  2004-06       Impact factor: 3.742

6.  Bioactivation of the cancer chemopreventive agent tamoxifen to quinone methides by cytochrome P4502B6 and identification of the modified residue on the apoprotein.

Authors:  Chitra Sridar; Jaime D'Agostino; Paul F Hollenberg
Journal:  Drug Metab Dispos       Date:  2012-08-31       Impact factor: 3.922

7.  Mutagenicity of tamoxifen DNA adducts in human endometrial cells and in silico prediction of p53 mutation hotspots.

Authors:  Evagelos Liapis; Keith I E McLuckie; Paul D Lewis; Peter B Farmer; Karen Brown
Journal:  Nucleic Acids Res       Date:  2008-09-19       Impact factor: 16.971

8.  Uterine carcinosarcoma/malignant mixed Müllerian tumor incidence is increased in women with breast cancer, but independent of hormone therapy.

Authors:  Brian T Wilson; Heather J Cordell
Journal:  J Gynecol Oncol       Date:  2015-09-23       Impact factor: 4.401

9.  The Food and Drug Administration Office of Women's Health: Impact of Science on Regulatory Policy: An Update.

Authors:  Merina Elahi; Noha Eshera; Nkosazana Bambata; Helen Barr; Beverly Lyn-Cook; Julie Beitz; Maria Rios; Deborah R Taylor; Marilyn Lightfoote; Nada Hanafi; Lowri DeJager; Paddy Wiesenfeld; Pamela E Scott; Emmanuel O Fadiran; Marsha B Henderson
Journal:  J Womens Health (Larchmt)       Date:  2016-02-12       Impact factor: 2.681

Review 10.  Selective estrogen receptor modulators: tissue specificity and clinical utility.

Authors:  Stephen Martinkovich; Darshan Shah; Sonia Lobo Planey; John A Arnott
Journal:  Clin Interv Aging       Date:  2014-08-28       Impact factor: 4.458

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.